Pipeline of Genital Herpes Market Covering 19 Companies and 17 Drug Profiles
PUNE, India, March 24, 2016 /PRNewswire/ --
New market research report titled "Genital Herpes - Pipeline Review, H2 2015" enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Company Profiles discussed in this report includes Admedus Ltd, AiCuris GmbH & Co. KG, AlphaVax, Inc., Foamix Pharmaceuticals Ltd., Genocea Biosciences, Inc., GenVec, Inc., Immune Design Corp., Immunovaccine, Inc., Mymetics Corporation, NanoBio Corporation, NanoViricides, Inc., PaxVax, Profectus BioSciences, Inc., Sanofi Pasteur SA, Spider Biotech, Starpharma Holdings Limited, Vaccibody AS, Vaxart, Inc. and Vical Incorporated.
Complete report on H2 2015 pipeline review of Genital Herpes with 37 market data tables and 14 figures, spread across 100 pages is available at http://www.rnrmarketresearch.com/genital-herpes-pipeline-review-h2-2015-market-report.html .
Drugs Profiles discussed in this research includes acyclovir, Aspidasept, astodrimer, G-103, GEN-002, GEN-003, genital herpes vaccine [HSV-2], GV-2207, HerpeCide-I, herpes simplex virus [serotype 2] vaccine, herpes simplex virus [type 1, 2] vaccine, herpes simplex virus [type 2] vaccine, HSV-529, pritelivir, SB-105A10, VCLHB-01 and VCLHM-01.
This report provides comprehensive information on the therapeutic development for Genital Herpes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Herpes and special features on late-stage and discontinued projects.
Order a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=419684 .
Scope of this report: The report provides a snapshot of the global therapeutic landscape of Genital Herpes. The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities and also key players involved in the therapeutics development for Genital Herpes and enlists all their major and minor projects summarizing all the dormant and discontinued pipeline projects. A review of the Genital Herpes products under development by companies and universities/research institutes based on information derived from company and industry-specific sources, pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages, detailed assessment of monotherapy and combination therapy pipeline projects, coverage of the Genital Herpes pipeline on the basis of target, MoA, route of administration and molecule type and latest news and deals relating related to pipeline products.
List of Tables:
Number of Products under Development for Genital Herpes, H2 2015
Number of Products under Development for Genital Herpes - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Genital Herpes Therapeutics - Recent Pipeline Updates, H2 2015
Genital Herpes - Dormant Projects, H2 2015
Genital Herpes - Dormant Projects (Contd..1), H2 2015
Genital Herpes - Discontinued Products, H2 2015
Another newly published market research report titled on Chlamydia Infections - Pipeline Review, H2 2015 provides comprehensive information on the therapeutic development for Chlamydia Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chlamydia Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Chlamydia Infections Pipeline market research report of 84 pages is available at http://www.rnrmarketresearch.com/chlamydia-infections-pipeline-review-h2-2015-market-report.html .
Explore more reports on Sexually Transmitted Diseases Therapeutics.
About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel: +1-888-391-5441
[email protected]
Connect with Us:
G+ / Google Plus: https://plus.google.com/104156468549256253075/posts
Twitter: https://twitter.com/RnRMR
Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345
SOURCE RnR Market Research
Share this article